Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03008018 · ClinicalTrials.gov registry record · Phase 1
Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours
A Phase 1 study, sponsored by Karus Therapeutics Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03008018 is a Phase 1 study that has completed, run by Karus Therapeutics Limited. The registered enrollment target is 20 participants.
The verdict
NCT03008018, a Phase 1 study, has completed, sponsored by Karus Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The aim of the study is to evaluate the safety/tolerability, pharmacokinetic, and pharmaco-dynamic effects of KA2507 and establish the maximum tolerated dose (MTD). Patients with PD-L1 expressing solid tumors which have relapsed or are refractory to prior treatment will be eligible to participate in this study. Following completion of the multiple ascending dose study, the protocol may be amended to include expansion cohorts in patients with melanoma and/or other solid tumors.
Interventions
- DRUG KA2507
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-08-07 |
| Est. Completion | 2020-06-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03008018
The ClinicalTrials.gov registry entry for NCT03008018 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Karus Therapeutics Limited, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KA2507 is the first listed.
NCT03008018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03008018 about?
NCT03008018 is a clinical study titled "Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours". The aim of the study is to evaluate the safety/tolerability, pharmacokinetic, and pharmaco-dynamic effects of KA2507 and establish the maximum tolerated dose (MTD). Patients with PD-L1 expressing solid tumors which have relapsed or are refractory to prior treatment will be eligible to participate in...
What is the current status of trial NCT03008018?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-08-07. Estimated completion is 2020-06-10.
What interventions are being tested in trial NCT03008018?
The interventions under investigation include: KA2507 (DRUG).
Who is sponsoring clinical trial NCT03008018?
This trial is sponsored by Karus Therapeutics Limited, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.